Inhibikase Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Inhibikase Therapeutics

12/08/2022 22:50

* Inhibikase Therapeutics Inc  IKT.OQ  reported a quarterly
adjusted loss of 18 cents​​ per share for the quarter ended in
June. The lone analyst forecast for the quarter was for a loss
of 19 cents per share.
    * Revenue fell 99.5% to $6.55 thousand from a year ago;
analysts
expected $300.00 thousand. 
    * Inhibikase Therapeutics Inc's reported EPS for the quarter
was a
loss of 18 cents​.
    * The mean earnings estimate of analysts had fallen by
about 5.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Inhibikase Therapeutics Inc shares had risen by 19.6% this
quarter and lost 39.6% so far this year.
    * The company reported a quarterly loss of $4.64 million.
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 12
at 09:50 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.19          -0.18          Beat
 Mar. 31 2022      -0.17          -0.18          Missed
 Dec. 31 2021      -0.17          -0.20          Missed
 Sep. 30 2021      -0.14          -0.18          Missed